https://orcid.org/0000-0002-4479-9390
References
- Gross JG, Glassman AR, Jampol ML et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015; 314: 2137–2146. doi:10.1001/jama.2015.15217
- Sivaprasad S, Prevost AT, Vasconcelos JC et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 2017; 389: 2193–2203.
- Gao S, Lin Z, Shen X. Anti-vascular endothelial growth factor therapy as an alternative or adjunct to pan-retinal photocoagulation in treating proliferative diabetic retinopathy: meta-analysis of randomized trials. Front Pharmacol 2020; 11: 849. doi:10.3389/fphar.2020.00849
- Brown DM, Wykoff CC, Boyer D et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the panorama randomized clinical trial. JAMA Ophthalmol 2021; 139: 946–955. doi:10.1001/jamaophthalmol.2021.2809
- Maturi RK, Glassman AR, Josic K et al. Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol w randomized clinical trial. JAMA Ophthalmol 2021; 139: 701–712. doi:10.1001/jamaophthalmol.2021.0606
- Obeid A, Su D, Patel SN et al. Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor. Ophthalmology 2019; 126: 407–413. doi:10.1016/j.ophtha.2018.07.027